Market cap: $3,946,509,940
Exchange: NAS
Sector: Health Technology
Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
Company Name
Mirati Therapeutics Inc
Average Volume (10 days)
2,591,138
Average Volume (30 days)
1,904,949
Moving Average (50 days)
$53.65
Moving Average (200 days)
$41.87
Ex-Divided Date
n/a
Dividend Yield
0
P/E Ratio
-5.4369
Market Cap
3,946,509,940
Shares Outstanding
70,147,706
52-Week High Split Adjust Only
101.3
52-Week Low Split Adjust Only
27.3
Employee Count
593
Beta
0.8918
Next Earnings Date
TTM Dividend Rate Per Share
0
Past 5 days
0%
Past 30 days
0.01%
Past 3 months
0.45%
Past 6 months
0.14%
Past year
-0.23%
Past 2 years
-0.6%
Past 5 years
0.51%
Max % Change
17.65%
| Name | Ticker | Price/Sales (ttm) | Price/Book (ttm) | Forward P/E | PEG Ratio | EV/Revenue |
|---|---|---|---|---|---|---|
| Mirati Therapeutics Inc | MRTX | 619.54 | 6.46 | -15.1 | 619.54 | 521.52 |
| Peer Avg | N/A | 2.23 | 4.53 | 13.2 | 2.23 | 2.39 |
| AMGEN Inc. | AMGN | 5.43 | 14.65 | 14.6 | 5.43 | 6.31 |
| Alkermes plc | ALKS | 3.48 | 3.46 | 44.8 | 3.48 | 3.25 |
| Aldeyra Therapeutics Inc | ALDX | n/a | n/a | -6.7 | n/a | n/a |